ABCL is the ticker symbol for AbCellera Biologics Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks ABCL with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is ABCL a good stock to buy?

13F Pro's AI ranking engine scores ABCL at 15.3/100, ranked #2,816 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for ABCL is available at https://13fpro.ai/company/ABCL. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source ABCL data?

All AbCellera Biologics Inc. fundamentals and ownership data come directly from SEC EDGAR. AbCellera Biologics Inc. files with the SEC under CIK 1703057. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

AbCellera Biologics Inc. ABCL

NasdaqMid CapHealthcare

13F Pro quality score

Rank #2,816 of 2,925

Why it scores 15 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$4.05M

Quarter to Jun 30

Net income

$-55.43M

Quarter to Jun 30

Free cash flow

$23.79M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026

$908.85M total

BAKER BROS. ADVISORS LP

$259.15M+9.0%

Capital World Investors

$106.67M+1.7%

TWO SIGMA INVESTMENTS, LP

$81.93M-1.2%

TD Waterhouse Canada Inc.

$72.62M0.0%

BANK OF AMERICA CORP /DE/

$48.21M+104.7%

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME

$33.89M-43.0%

ArrowMark Colorado Holdings LLC

$32.22M0.0%

BlackRock, Inc.

$29.87M-5.8%

DRIEHAUS CAPITAL MANAGEMENT LLC

$22.49M-28.8%

TUDOR INVESTMENT CORP ET AL

$16.20M-9.3%

MARSHALL WACE, LLP

$14.93M+428.9%

UBS Group AG

$14.68M-55.6%

MORGAN STANLEY

$13.10M-25.0%

PRICE T ROWE ASSOCIATES INC /MD/

$12.46MNew

CITADEL ADVISORS LLC

$12.45M+16.6%

NATIONAL BANK OF CANADA /FI/

$9.68MNew

ARROWSTREET CAPITAL, LIMITED PARTNERSHIP

$8.16MNew

RENAISSANCE TECHNOLOGIES LLC

$7.78M-34.4%

Counterpoint Mutual Funds LLC

$7.63MNew

STATE STREET CORP

$5.74M+0.2%

HRT FINANCIAL LP

$5.54M-42.9%

DnB Asset Management AS

$5.32MNew

Guardian Partners Inc.

$4.68M-66.6%

Intellectus Partners, LLC

$4.33M+1.0%

Alyeska Investment Group, L.P.

$4.13M-79.7%

See all 151 institutional holders →

What's Driving ABCL's Business? Latest 10-Q Breakdown

34/34 datapoints verified

AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q2 revenue collapsed 76% YoY to $4.1M as licensing fees evaporated, offset by $56M upfront from Jazz collaboration and $28M from Vertex deal signed post-quarter.

Biggest Revenue Drivers

Research fees$3.9M-41% YoY

Decreased from timing and progress of research and development efforts

Licensing and royalty revenue$0.1M-99% YoY

Minimal licensing revenue recognized in Q2 2026 versus Q2 2025

Biggest Revenue Drivers

Total revenue: $4.1M-76% YoY

Research fees$3.9M-41% YoY

Decreased from timing and progress of research and development efforts

Licensing and royalty revenue$0.1M-99% YoY

Minimal licensing revenue recognized in Q2 2026 versus Q2 2025

Largest Expense Items

Research and development$46.0M+17% YoY

External clinical program costs $5.1M (ABCL575, ABCL635 clinic entry); compensations $22.2M, unallocated internal costs $11.7M

Sales, general, and administrative$13.9M-37% YoY

Optimization of headcount and reduction in legal fees following December 2025 settlement

Depreciation and amortization$7.0M+28% YoY

Increase driven by clinical manufacturing facility depreciation starting December 2025

Margins: Operating loss widened to $62.8M from $49.6M YoY despite SG&A savings, as revenue collapsed while R&D spending increased 17% to advance ABCL635 Phase 2 and ABCL575 Phase 1 clinical programs. Interest income swing from $9.5M gain to $0.04M loss due to currency headwinds and lower yields.

Watch Items from the Filing

ABCL635 Phase 2 top-line readout expected August 2026; interim Phase 1 data (May 2026) showed potent biomarker reduction and no liver toxicity, but early-stage data carries significant execution risk.
Jazz Pharmaceuticals upfront of $56M received Q2 2026; additional $28M due on third program initiation within 12 months; potential $792M per-program in milestone and royalty terms contingent on Jazz exercise and commercial success.
Accumulated deficit swung to $128.1M at June 30, 2026 from $29.5M earnings at December 31, 2025; company burning ~$7.6M cash in H1 2026 and expects 36+ months liquidity from current $540M in cash and securities.
Government contribution agreements with Canada and BC provide CAD $156.1M ($110M) in remaining available non-dilutive funding through 2033, subject to revenue thresholds and repayment conditions.
Partner-led programs with downstreams decreased from 44 to 35; molecules in clinic decreased from 14 to 12; visibility into partner program progress limited and economic stakes small for Trianni-licensed programs.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q2 2026

EDGAR

Net Income

Q2 2026

EDGAR

EPS (Diluted)

Q2 2026

EDGAR

ROIC

Q2 2026

EDGAR

Free Cash Flow

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ABCL

Earnings Per Share

13fpro.ai/company/ABCL

Loading ratio trend…

AbCellera Biologics Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$75.1M	$-146.4M	—
FY 2024	10-K	$28.8M	$-162.9M	—
FY 2023	10-K	$38.0M	$-146.4M	—
FY 2022	10-K	$485.4M	$158.5M	44.6%
FY 2021	10-K	$375.2M	$153.5M	54.5%
FY 2020	10-K	$233.2M	$118.9M	66.9%

About AbCellera Biologics Inc. (ABCL): stock profile, AI score and financials

AbCellera Biologics Inc. (ABCL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ABCL at 15.3/100 on a composite quality score built from its SEC filings, placing it at rank #2,816 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (3.6) and free cash flow (3.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), AbCellera Biologics Inc. reports quarterly revenue of $4.0M, net income of $-55.4M, free cash flow of $23.8M. Top institutional holders of ABCL by reported 13-F value include BAKER BROS. ADVISORS, Capital World Investors, TWO SIGMA INVESTMENTS, based on the most recent SEC filings. ABCL trades on the Nasdaq exchange and files with the SEC under CIK 1703057. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABCL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AbCellera Biologics Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1703057 →

AbCellera Biologics Inc. ABCL

Top Institutional Holders

What's Driving ABCL's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

ABCL key financials by period

ABCL insiders

About AbCellera Biologics Inc. (ABCL): stock profile, AI score and financials

AbCellera Biologics Inc. ABCL

Top Institutional Holders

What's Driving ABCL's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

ABCL key financials by period

Companies similar to ABCL

ABCL insiders

About AbCellera Biologics Inc. (ABCL): stock profile, AI score and financials